EICHOR
● Recruiting
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Condition: Small Cell Lung Cancer · Sponsor: Tang-Du Hospital
About this study
This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.
This description comes directly from the study's public registry record.
Talk to the study team
Haichuan Su, PhD · 18629190366 · such@fmmu.edu.cn
Jie Min, PhD · 13709202616 · minjie1504@163.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Tangdu Hospital | Xi'an, Shannxi, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06467786